Company / Net Income
Biogen Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
$1.3B
FY2025
5-year range
$1.2B / $3.0B
FY2021-FY2025
Trend
-20.8%
vs FY2024
Sector context
#15 of 214
Health Care
What the data says
Among 214 Health Care companies, Biogen is in the top 7% for net income. Net Income has fluctuated over the past 10 years, ranging from $1.2B in FY2023 to $5.9B in FY2019.
Based on SEC 10-K filings.
$1.3B in FY2025 with a 5-year CAGR of -20.2%. Top quartile in the Health Care sector.
Improved from $1.2B to $1.3B over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -24.9%
- 5-Year CAGR
- -20.2%
- 10-Year CAGR
- -
Sector benchmark
Top 7% in Health CareTop 7% of 214This company $1.3B Sector average $443.1M
▼
+191.8% above sector average
Key checks
Key Insights
- 5-year CAGR of -20.2%, indicating a declining trend.
- In FY2025, net income decreased 20.8% year-over-year.
- Ranks #15 out of 214 companies in the Health Care sector.
- Peak net income was recorded in FY2019.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.3B | -20.8% |
| FY2024 | $1.6B | +40.6% |
| FY2023 | $1.2B | -61.9% |
| FY2022 | $3.0B | +95.8% |
| FY2021 | $1.6B | -61.1% |
| FY2020 | $4.0B | -32.1% |
| FY2019 | $5.9B | +32.9% |
| FY2018 | $4.4B | +74.5% |
| FY2017 | $2.5B | -31.4% |
| FY2016 | $3.7B | +4.4% |
As of FY2025 · SEC 10-K · Updated Mar 3, 2026